Depomed, Inc. To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., May 9, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two upcoming investor conferences:

Bank of America Merrill Lynch Healthcare Conference in Las Vegas Nevada on Thursday May 15 at 11:00 am Eastern Time (8:00 am Pacific Time).

UBS Global Healthcare Conference in New York City on Monday May 19 at 9:00 am Eastern Time (6:00 am Pacific Time).

The presentations will be webcast, and the webcasts can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of each webcast will be archived for 30 days on the company's website.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

CONTACT: August J. Moretti
Depomed, Inc. 510.744.8000
amoretti@depomed.com

SOURCE Depomed



Help employers find you! Check out all the jobs and post your resume.

Back to news